Semanteon Capital Management LP Purchases Shares of 2,758 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Semanteon Capital Management LP purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 2,758 shares of the biopharmaceutical company’s stock, valued at approximately $759,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ALNY. Capital Research Global Investors raised its stake in Alnylam Pharmaceuticals by 7.3% in the first quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock valued at $470,018,000 after buying an additional 214,908 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Alnylam Pharmaceuticals by 5.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock valued at $550,837,000 after purchasing an additional 201,784 shares during the period. AQR Capital Management LLC increased its holdings in shares of Alnylam Pharmaceuticals by 92.5% in the second quarter. AQR Capital Management LLC now owns 271,619 shares of the biopharmaceutical company’s stock valued at $65,862,000 after purchasing an additional 130,482 shares during the period. Jacobs Levy Equity Management Inc. acquired a new position in shares of Alnylam Pharmaceuticals in the first quarter valued at about $18,886,000. Finally, Deerfield Management Company L.P. Series C acquired a new stake in Alnylam Pharmaceuticals during the second quarter worth about $29,111,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Up 1.8 %

ALNY stock traded up $5.19 during mid-day trading on Monday, hitting $290.05. 11,831 shares of the company were exchanged, compared to its average volume of 865,751. The firm has a market capitalization of $36.69 billion, a P/E ratio of -106.29 and a beta of 0.39. The business has a fifty day simple moving average of $274.43 and a 200-day simple moving average of $222.40. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.61. The business had revenue of $659.83 million for the quarter, compared to analyst estimates of $447.22 million. The firm’s revenue for the quarter was up 107.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($2.21) EPS. Research analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.73 EPS for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, Director Dennis A. Ausiello sold 20,250 shares of the stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the sale, the director now owns 136 shares of the company’s stock, valued at approximately $35,632. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Yvonne Greenstreet sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total value of $4,200,000.00. Following the sale, the chief executive officer now owns 73,441 shares of the company’s stock, valued at $20,563,480. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Dennis A. Ausiello sold 20,250 shares of the firm’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the completion of the sale, the director now directly owns 136 shares in the company, valued at approximately $35,632. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 50,398 shares of company stock valued at $13,595,460. 1.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts recently commented on ALNY shares. Citigroup raised their target price on Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Cantor Fitzgerald restated a “neutral” rating and set a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, October 11th. The Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $198.00 to $370.00 in a research report on Friday, August 16th. TD Cowen upped their price objective on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Finally, Barclays upped their price objective on shares of Alnylam Pharmaceuticals from $291.00 to $295.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Six investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $290.86.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.